RAYMOND JAMES & ASSOCIATES - GALMED PHARMACEUTICALS LTD ownership

GALMED PHARMACEUTICALS LTD's ticker is GLMD and the CUSIP is M47238106. A total of 39 filers reported holding GALMED PHARMACEUTICALS LTD in Q3 2018. The put-call ratio across all filers is 34.00 and the average weighting 0.3%.

Quarter-by-quarter ownership
RAYMOND JAMES & ASSOCIATES ownership history of GALMED PHARMACEUTICALS LTD
ValueSharesWeighting
Q1 2023$58,874
-14.7%
138,0400.0%0.00%
Q4 2022$69,020
+40.9%
138,040
-11.5%
0.00%
Q3 2022$49,000
-52.0%
155,940
-1.0%
0.00%
Q2 2022$102,000
-68.4%
157,440
-22.4%
0.00%
Q1 2022$323,000
-12.7%
202,940
-0.3%
0.00%
Q4 2021$370,000
-42.3%
203,540
-11.4%
0.00%
-100.0%
Q3 2021$641,000
+1.4%
229,640
+10.5%
0.00%0.0%
Q2 2021$632,000
+23.7%
207,865
+39.5%
0.00%0.0%
Q1 2021$511,000
+16.9%
148,971
+6.1%
0.00%
Q4 2020$437,000
-45.8%
140,365
-38.6%
0.00%
-100.0%
Q3 2020$807,000
-68.4%
228,569
-57.2%
0.00%
-66.7%
Q2 2020$2,555,000
+114.5%
534,609
+55.3%
0.00%
+50.0%
Q1 2020$1,191,000
-48.9%
344,195
-14.7%
0.00%
-33.3%
Q4 2019$2,333,000
+92.0%
403,559
+58.7%
0.00%
+50.0%
Q3 2019$1,215,000
+45.0%
254,265
+123.1%
0.00%
+100.0%
Q2 2019$838,000
+17.5%
113,965
+30.7%
0.00%0.0%
Q1 2019$713,000
+21.1%
87,225
+1.2%
0.00%0.0%
Q4 2018$589,000
-40.1%
86,201
+19.0%
0.00%
-50.0%
Q3 2018$984,00072,4370.00%
Other shareholders
GALMED PHARMACEUTICALS LTD shareholders Q3 2018
NameSharesValueWeighting ↓
BVF INC/IL 1,878,508$12,830,0001.68%
Knoll Capital Management, LLC 210,000$1,434,0001.63%
Vivo Capital, LLC 971,337$6,634,0000.85%
P.A.W. CAPITAL CORP 90,000$615,0000.77%
683 Capital Management, LLC 1,350,000$9,221,0000.56%
Ibex Investors LLC 500,000$3,415,0000.56%
MEITAV INVESTMENT HOUSE LTD 653,667$4,465,0000.28%
FIRST MIDWEST BANK TRUST DIVISION 214,872$1,468,0000.22%
Nantahala Capital Management 834,401$5,699,0000.18%
PREMIER ASSET MANAGEMENT LLC 73,950$505,0000.14%
View complete list of GALMED PHARMACEUTICALS LTD shareholders